Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer Patients with metastatic colorectal cancer (mCRC) harboring BRAF V600E mutations benefited from first-line treatment with the targeted therapies encorafenib and cetuximab plus a mFOLFOX6 chemotherapy regimen, according to results from the PhaseIII BREAKWATER trial. Read more …Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated...
Sewage leaks and ops delayed - life at hospitals awaiting rebuild A host of hospital building projects have been put back to the 2030s. How will they cope?...Read more https://www.bbc.com/news/articles/clyelwnq32go
New drug shows promise in restoring vision for people with nerve damage Researchers have found a promising drug candidate that could help restore vision in individuals with multiple sclerosis (MS) and other neurological conditions that damage neurons. Read more …New drug shows promise in restoring vision for people with nerve damage
Scientists design peptides to enhance drug efficacy Scientists have developed a groundbreaking approach using specially designed peptides to improve drug formulations. This innovative method significantly enhances anti-tumor efficacy. Read more …Scientists design peptides to enhance drug efficacy